S&P Capital IQ Equity Analyst Herman Saftlas joins Brian Egli, S&P Capital IQ Editorial, to discuss diabetes and where investment opportunities might lie with companies that are fighting this disease such as Johnson & Johnson (JNJ) . To read this and all Trends & Ideas content, please visit www.marketscope.com.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer